AIM ImmunoTech Inc

(AIM, NYSE)

$2.01

-$0.04
(-0.02%)
PE Ratio
1.35
EPS
-$7.70
Market Cap
$83M
52 Week Range
$1.60 - $7.11
Operating Margin
-7608.77%
Dividend & Yield
$0.00 (0.00%)
Volume
NaN
Rev. per Share
$0.01

About AIM ImmunoTech Inc

AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. It is also developing Ampligen for the treatment of Hepatitis B and HIV, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. AIM ImmunoTech Inc. has research agreement with the Japanese National Institute of Infectious Diseases and Shionogi & Co., Ltd. to test its drug Ampligen as an adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was founded in 1966 and is headquartered in Ocala, Florida.

Earnings

News about AIM ImmunoTech Inc

City AM
Yesterday
AIM outperforms London’s main market during 12 months of Covid-19
This is Money
Yesterday
AIM outperforms Stock Exchange's main market
Stock Market Daily
last Friday
AIM ImmunoTech Wall street estimates Earnings report Stock market Insights & financial analysis
Daily Mail Online
last Thursday
Should you buy AIM shares to reduce inheritance tax?
VOX Markets
last Thursday
Savannah Resources - Mina do Barroso Lithium Project Update - Vox Markets
Accuracy In Media
last Wednesday
Cuomo in trouble! AIM’s Adam Guillette discusses on OAN
Accuracy In Media
03/02/2021
Is Dr. Seuss racist? AIM’s Adam Guillette discusses on Fox Business
Evening Standard
02/25/2021
Virgin Wines confirms £110 million AIM float
AIM ImmunoTech
02/24/2021
AIM ImmunoTech's Subsidiary Receives Orphan Medicinal Product Designation by the European Medicines Agency for Ampligen to Treat Pancreatic Cancer - AIM ImmunoTech Inc.
Business Wire
02/23/2021
Agricultural Institute of Marin (AIM) Unveils 3-Year Strategic Plan: Paradigm-Shifting Model for Resilient Local & Regional Food Systems

AIM ImmunoTech Inc

Type
Sector
Healthcare
Industry
Biotechnology
About kinfo
Kinfo is an app for DIY traders and investors. Kinfo tracks your trading performance and lets you compare measurable performance metrics against other traders. Kinfo works for day trading, swing trading and longer holding periods. By tracking portfolio performance kinfo allows traders to learn, find inspiration and gain confidence.
Get Social
Download the App

Trading involves significant risk of loss. It is not suitable for all investors and you should make sure you understand the risks involved, seeking independent advice if necessary.

Never risk more than you are willing to lose. Trading futures and other derivatives may cause losses that exceed deposits.

Hypothetical performance results have inherent limitations, some of which are described below. Kinfo makes no representation that any trading account will or is likely to achieve profits or losses like those shown. There are often sharp differences between hypothetical trading performance results and the actual results subsequently achieved by any trading program. Past results of advertised trading systems, profit statements, charts or any other representations are not indicative of future performance.

Kinfo is an educational site and is not a financial adviser or broker. All stocks, ETFs, commodities, Indices, Forex, Bonds, and other securities mentioned in our courses are for educational and illustrative purposes only. If you need professional investment advice, please consult a registered investment adviser. Futures and Options carry risk and may not be suitable for everyone.

Kinfo demonstrates specific advanced approaches (or methods). Any mention of Return of Investment percentages is only indicative of the potential of the strategy or the system and is not meant to signify any guaranteed returns.

Success in trading involves a range of human factors like decision making skills, adjustment skills, emotional control, and risk management and other psychological and behavioral parameters, all of which are completely in the hands of the individual. Trading involves significant risk of loss. It is not suitable for all investors.

Charts on kinfo provided by TradingView